Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NVS: Novartis AG -- Ignore unavailable to you. Want to Upgrade?

To: Starlight who wrote (35)	5/16/2001 1:08:33 PM
From: t2	Read Replies (1) \| Respond to of 116

Elizabeth, Thanks for that great article. The point to remember is that as far as US investors are concerned, this is a new name to be added to porfolios. The focus among general US equity funds is to buy US based drug stocks. The good new from NVS basically puts it on the buy list for many funds. That explains its relative strength yesterday versus its US peers. The cancer treatments news was already out last week with the additional news from the weekend being digested by the market on Monday. That is why Tuesday's price action was significant,IMHO. The under ownership among US funds is a HUGE factor for its stock price going forward.